XERS Projected Dividend Yield

Xeris Biopharma Holdings Inc ( NASDAQ : XERS )

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which is focused on improving patients' lives by developing and commercializing products across a range of therapies. It has three commercial products. Gvoke is a ready-to-use, liquid-stable glucagon for the treatment of severe hypoglycemia. Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome for whom surgery is not an option or has not been curative. Keveyis is the first therapy approved in the U.S. to treat hyperkalemic, hypokalemic, and related variants of Primary Periodic Paralysis (PPP).

20 YEAR PERFORMANCE RESULTS